LDLR and atherosclerosis: We created a Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9)‐induced low‐density lipoprotein receptor (LDLR) knockdown model of hyperlipidemic atherosclerosis[22] to verify that HM13/SPP accelerates atherogenesis.